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Abstract
Objective To assess the association between gastro-intestinal (GI) symptoms and health-related quality of life (HRQoL) in
ovarian cancer (OC) survivors.
Methods Women diagnosed with OC between 2000 and 2010 as registered in the Netherlands cancer registry (n = 348), received
a questionnaire on socio-demographic characteristics, HRQoL (EORTC-QLQ-C30), ovarian cancer-specific symptoms includ-
ing GI (EORTC-QLQ OV28), and psychological distress (HADS). Data collection took place in 2012.
Results Of 348 women diagnosed with ovarian cancer, 191 (55%) responded. Of all participants, 69% were eligible for analysis
(n = 131). In 25% of all women, high level GI symptoms occurred (n = 33). In 23% of all women, recurrence of OC occurred (n =
30). Regression analysis showed that presence of high levels of GI symptoms during survivorship was associated with lower
functioning on all HRQoL domains (except for emotional functioning), more symptoms, and higher levels of distress. QoL was
negatively affected in those who had few and high levels of GI symptoms. QoL of those with recurrent disease was worse than
those without recurrent disease.
Conclusion A substantial proportion of OC survivors experience GI symptoms, regardless of the recurrence of disease. Health
care professionals should be aware of GI symptoms during survivorship in order to refer their patients for supportive care
interventions to reduce symptoms or help survivors to cope. Further research should examine the cause of GI symptoms during
OC survivorship among those with non-recurrent disease.
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Introduction
Ovarian cancer (OC) is the third most common gynecological
malignancy worldwide and the fifth leading cause of cancer-
related death among women [1, 2]. In the Netherlands, about
1300 cases of OC are diagnosed annually [3, 4]. Due to vague
nature of symptoms, the disease is usually diagnosed at an
advanced disease stage: up to 70% of all patients is diagnosed
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with stage III/IV disease, with extensive involvement of the
abdominal cavity [5, 6]. Up to 70% of all patients experience
recurrent disease [7, 8].Overall, the most frequently reported
symptoms at time of OC diagnosis and eventual recurrence are
pain, abdominal swelling or distension, unusual fatigue,
bloating, weight change, dyspepsia, vomiting, altered bowel
habits, urinary, and gastro-intestinal (GI) symptoms [5, 9–11].
Standard therapy consists of surgery and chemotherapy [12].
Despite effective initial treatment, overall 5-year survival rates
fluctuate from 90% for early-stage disease to 40% for late-
stage disease [6, 13].
Some OC survivors may return to their normal functioning
and life after the initial treatment, but others survivors will
experience a wide range of sequelae related to cancer or its
treatment that do not dissipate with time and may result in
diminished post-treatment functioning [9, 10].
The most frequently reported problems among OC survi-
vors are fatigue, pain, neuropathy, and concerns about getting
cancer under control, recurrence, and death [14–19]. Two re-
cent studies revealed that GI symptoms are a common prob-
lem among OC survivors who underwent surgery alone or
surgery followed by chemotherapy [12, 16]. Research among
survivors of other cancer types who received abdominal ra-
diotherapy revealed that up to 40% reported moderate or se-
vere GI symptoms, which had a negative impact on their
health-related quality of life (HRQoL) [20]. GI symptoms
are commonly reported as symptoms at first presentation of
OC or disease recurrence; experiencing these symptoms dur-
ing survivorship may cause significant distress and deteriorat-
ed HRQoL among OC survivors as these symptoms remind
them of their disease [21]. However, up to now, no studies
address this issue in population-based cohort of both short-
and long-term cancer survivors. Therefore, the aims of this
study were to assess (1) the prevalence of GI symptoms strat-
ified by recurrence status and (2) the relationship of GI symp-
toms with HRQoL and distress among OC survivors.
Methods
Setting and participants
A cross-sectional study was conducted among women diag-
nosed with ovarian cancer between January 1, 2000 and
July 1, 2010, as registered in the Netherlands Cancer
Registry (NCR), in six hospitals in the southern region of
the Netherlands. To be eligible, women had to have been
diagnosed with ovarian cancer between January 1, 2000 and
July 1, 2010, have an adequate literacy level to understand the
questionnaire, speak and understand Dutch, have been treated
in one of the affiliated hospitals, and had to be alive at the time
of the study. Vital status was established either by the hospital
patient file or by linking the NCR with the Central Bureau of
Genealogy; 693 were deceased according to the Central
Bureau of Genealogy and therefore excluded. Of 1147 regis-
tered women, 693 were identified as deceased according to the
Central Bureau of Geneology and 106 were identified as de-
ceased, hospitalized, or staying in a nursing home according
to the hospital patient file. The remaining 348 received a ques-
tionnaire (Fig. 1). This study was approved by a regional
ethical committee (St. Elisabeth Hospital, no. 1149).
Procedures/data collection
All patients received an information letter from their gynecol-
ogist, and after signing the informed consent form about
linking the results of the questionnaires with the NCR data,
the questionnaires were completed. Data collection took place
in 2012 and was done within PROFILES (Patient Reported
Outcomes Following Initial treatment and Long term
Evaluation of Survivorship). PROFILES is a registry to study
the physical and psychosocial impact of cancer and its treat-
ment in a dynamic, growing population-based cohort of both
short- and long-term cancer survivors. PROFILES contains a
large web-based component and is linked directly to clinical
data from the NCR. Details of the data collection method have
been previously described [22]. Data from the PROFILES
registry are available for non-commercial scientific research,
subject to study question, privacy and confidentiality restric-
tions, and registration (www.profilesregistry.nl).
Measures
Socio-demographic and clinical characteristics
Clinical and patient information was obtained from the NCR
(i.e., date of birth, date of diagnosis, disease stage, and prima-
ry treatment) [23]. The questionnaire included questions on
socio-demographic characteristics (i.e., marital status, em-
ployment status, and educational level). Comorbidity at the
time of survey was assessed using the self-administered co-
morbidity questionnaire (SCQ) [24].
HRQoL
The EORTC QLQ-C30 version 3.0 (European Organization for
Research and Treatment of Cancer Quality of Life, quality of life
core questionnaire) was used to assess HRQoL [25]. It contains
five functional scales on physical, role, cognitive, emotional,
and social functioning, a global health status/QoL scale; three
symptom scales on fatigue, nausea and vomiting, and pain; and
six single items. The questions were framed as Bduring the past
week…^. Response scales included: BNot at all,^ BA bit,^
BQuite a bit,^ and BVery much,^ except for the global QoL
scale, which ranges from BVery poor^ to BExcellent.^ Scores
were linearly transformed to a 0–100 scale [26].
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Presence of GI symptoms
Disease-specific HRQoL, including GI symptoms, were
assessed with the EORTC QLQ-OV28 (Ovarian cancer mod-
ule) [27]. The QLQ-OV28 module contains seven scales:
abdominal/gastrointestinal symptoms, peripheral neuropathy,
other chemotherapy side effects, hormonal/menopausal symp-
toms, body image, attitude to disease/treatment and sexual
functioning. Abdominal symptoms are abdominal pain, feeling
bloated, clothes too tight, changed bowel habit, flatulence, full-
ness when eating, indigestion. Peripheral neuropathy symptoms
are tingling, numbness, and weakness. Other chemotherapy-
related side effects are hair loss and upset by hair loss, taste
change, muscle pain, hearing problem, urinary frequency, and
skin problems. Hormonal/menopausal symptoms are hot
flashes and night sweat. Body image-related symptoms are
feeling less attractive and dissatisfied with the body. Attitude
towards disease and treatment are described using disease bur-
den, treatment burden, and worry about future. Symptoms of
sexual dysfunctioning are rated using interest in sex, sexual
activity, enjoyment of sex, and lubrication [27, 28].
The GI symptoms scale consists of six questions: BDid you
have abdominal pain?,^ BDid you have a bloated feeling in
your abdomen/stomach?,^ BDid you have problems with your
clothes feeling too tight,^ BDid you experience change in bowel
habit as a result of your disease and treatment,^ BWere you
troubled by passing wind/gas/flatulence^ and BDid you feel full
too quickly after beginning to eat.^ The questions were framed
as Bduring the past week…^. Response scales included BNot at
all,^ BA bit,^ BQuite a bit,^, and BVery much.^ Scores were
linearly transformed to a 0–100 scale [26]. Our data revealed a
Cronbach’s alphas of 0.80 for the GI symptom subscale.
Psychological distress
The Hospital Anxiety and Depression Scale (HADS) was
used to assess psychological distress. The HADS is a 14-item,
self-report measure of anxiety and depression [29, 30]. Each
item is rated on a scale from 0 (not at all) to 3 (very much). The
HADS has two subscales (anxiety and depression) and a total
score. Meta-analysis of Norton et al. showed that the HADS
does not provide good separation between the subscales anx-
iety and depression [31]. Therefore, we only used the total
score to describe the psychological distress of the patients
[32]. Higher scores imply more psychological distress.
Statistical analysis
All statistical analyses were conducted using IBM SPSS
Statistics version 22 (SPSS Inc., Chicago, IL, USA). p values
of < 0.05 were considered statistically significant. Multi-item
scales of the EORTCQLQ-C30 were only computed if at least
half of the items from a scale were completed, according to the
EORTC QLQ-C30 scoring guidelines [24].
The GI symptom scale was dichotomized as 0 to 30 (high
level of GI symptoms) versus ≥ 30 to 100 (low level of GI
symptoms). This conservative cut-off point was pragmatically
chosen.
Frequencies and percentages were used to summarize cat-
egorical data. Means and standard deviations were used to
1147 women were diagnosed and registered 
with ovarian cancer between January 1st 2000 
and July 1st 2010 in 6 hospitals in the southern 
region of the Netherlands Cancer Registry 
(NCR)
454 paents are sll alive on Sept 15th, 2011. 
Gynecologists sent their (former) paents a 
leer to inform them about the study and a 
link to the quesonnaire
693 paents deceased 
- 1 hospital declined parcipaon 
(N=74)
- 29 paents furthermore excluded 
(deceased, hospitalized, nursing 
home)
Quesonnaires were sent to the remaining 
348 paents 
157 paents did not respond
191 paents responded (55%)
60 paents excluded due to missing 
data on recurrent disease
131 paents eligible for analysis
Fig. 1 Flowchart of the data
collection process
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summarize continuous data. Socio-demographic and clinical
characteristics of patients who had GI symptoms during sur-
vivorship versus those who had lower levels of GI symptoms
were compared using independent samples t tests for contin-
uous variables and chi-square tests for categorical variables
(Table 1).
Descriptives of items of the GI symptom scale were pre-
sented stratified by patients with versus those without recur-
rent disease and were compared using t tests for continuous
and chi-square tests for categorical variables (Fig. 2).
Descriptives were presented for the total group (Table 2).
Patients who had high levels of GI symptoms during survi-
vorship versus those who had low levels of GI symptomswere
compared using t tests for continuous and chi-square tests for
categorical variables. Thereafter, clinically important differ-
ences were determined between the low and high GI symptom
groups based upon published guidelines for the EORTC
QLQ-C30 and upon Norman’s rule of thumb for the OV-28
questionnaire [33]. Norman’s rule of thumb states that differ-
ences between groups of half a SD or more can be regarded
clinically significant [34]. Descriptives were presented strati-
fied by patients with versus those without recurrent disease
(supplement Table 3).
Multiple linear regression analyses were performed to eval-
uate the association between low or high level of GI symp-
toms (dichotomized item) and the HRQoL scales (dependent
variable). A priori we included presence of recurrent disease
(no vs. yes), total psychological distress (total score on
HADS), presence of comorbidities (no vs. yes), time since
diagnosis (years), and age at time of questionnaire completion
(years) as confounders.
Results
Patient characteristics
Of the 348 OC survivors, 191 responded to the questionnaire
(55%, Fig. 1). Sixty women (17%) were excluded due to lack-
ing information on the presence of recurrent disease, 131 par-
ticipants were eligible for analysis (38% of the invited pa-
tients, 69% of the respondents) of which 101 (77%) had
non-recurrent disease and 30 (23%) experienced recurrent dis-
ease. Socio-demographic and clinical characteristics did not
differ between patients with high and low levels of GI symp-
toms (Table 1).
GI symptoms
Twenty five percent of the patients (n = 33) reported high levels
of GI symptoms (Table 1). Of the 101 patients who had non-
recurrent disease, 20 (20%) experienced high levels of GI
symptoms, while 13 of the 30 (43%) patients with recurrent
disease experienced high levels GI symptoms. Women who
were suffering from recurrent disease more often significantly
experienced high levels of GI symptoms (odds ratio 6.3 p =
0.01; not tabulated) and scored significantly higher on three
(presence of abdominal pain, bloated feeling, and change in
bowel habits) of six of the GI symptom items (Fig. 2).
HRQOL domains of functioning and symptoms
Descriptive statistics on HRQoL scores were tabulated for the
total group (Table 2) and stratified for patients with versus
those without recurrent disease (Supplement Table 3).
In univariate analyses, significant differences were found
between survivors with high and low levels of GI symptoms
in all HRQoL functional scales (Table 2). Furthermore, pa-
tients suffering from high level of GI symptoms reported a
worse overall QoL (p = 0.00) and higher levels of (cancer-
related) symptoms (0.00 ≤ p ≤ 0.04). Lastly, patients suffering
from GI symptoms more often had distress (p = 0.00) com-
pared to those without GI problems. All differences were of
small to large clinical importance. Descriptives of recurrent
versus non recurrent disease have been described in supple-
ment Table 3. Presence of recurrent disease in those with high
levels of GI symptoms did not change the levels of HRQoL
(functioning and symptoms) or distress. In those with low
levels of GI symptoms with recurrent disease, HRQoL scores
revealed to be worse compared to those with high level of GI
symptoms and recurrent disease (supplement Table 3).
In multivariate analyses, patients with higher levels of GI
symptoms scored lower on all HRQoL functioning scales and
higher on all symptom scales, except emotional functioning
(p = 0.15), financial problems (p = 0.67), and sexuality (p =
0.18), compared to patients without GI symptoms.
Discussion and conclusions
In this study, 25% of OC survivors reported having high levels
of GI symptoms, regardless of presence of recurrent disease.
GI symptoms may have an impact on the well-being of survi-
vors because they are debilitating and act as a reminder of
disease and treatment [21] and as a presenting symptom for
recurrent disease [5, 9, 10]. In line with this, we found that OC
survivors without recurrent disease with high GI complaints
reported higher levels of distress than patients with low levels
of GI symptoms. Those with low levels of GI symptoms and
recurrent disease have a worse level of functioning and more
symptoms on various domains compared to those with low
levels of GI symptoms without recurrent disease or those with
high levels of GI symptoms.
Our study adds to the current literature by showing that OC
survivors with andwithout recurrent disease who experienceGI
complaints reported significantly more symptoms, including
2288 Support Care Cancer (2019) 27:2285–2293
Table 1 Socio-demographic and clinical characteristics of ovarian cancer survivors, according to presence of abdominal symptoms (n, %)
High level of GI symptomsA
(n = 33, 25%)
Low level of GI symptomsA
(n = 98, 75%)
p value*
Age at time of survey, years (mean, range, SD) 65 (48–88, 11) 65 (40–85, 10) 0.84
Years since diagnosis years (mean, range, SD) 5.7 (1.9–12.2, 3.2) 6.3 (1.93–12.3, 3.1) 0.37
FIGO stage at diagnosis (n, %)
I 11 (33) 46 (47)
II 7 (21) 14 (14)
III 12 (36) 32 (33)
IV 3 (9) 5 (5) 0.22
Treatment (n, %)
Surgery 1 (3) 4 (4)
Surgery+ CTx 32 (97) 92 (94)
CTx 0 (0) 1 (1)
Other 0 (0) 1 (1) 0.72
Comorbidities (n, %)
No 9 (27) 35 (36)
Yes 24 (73) 63 (64) 0.38
Most frequent comorbidities (n, %)
Backache 13 (39) 22 (22) 0.38
Arthritis 12 (36) 30 (31)
Hypertension 7 (21) 25 (26)
Socio-economic status (n, %)
High 8 (24) 35 (36)
Middle 16 (49) 38 (39)
Low 9 (27) 22 (22)
Missing 0 (0) 3 (3) 0.42
Educational level (n, %)
High 3 (9) 13 (13)
Medium 23 (70) 64 (65)
Low 4 (12) 19 (19)
Missing 3 (9) 2 (2) 0.58
Employed (n, %)
No 21 (64) 73 (75)
Yes 7 (21) 19 (19)
Missing 5 (15) 6 (6) 0.61
Marital status at time of survey (n, %)
Partner 22 (67) 63 (64)
No partner 9 (27) 35 (36)
Missing 2 (6) 0 (0) 0.52
Marital status at time of diagnosis (n, %)
Partner 22 (67) 61 (62)
No partner 3 (9) 3 (3)
Missing 8 (24) 34 (35) 0.22
Presence of recurrent disease (n, %)
No 20 (61) 81 (83)
Yes 13 (39) 17 (17) 0.22
*T tests for continuous and chi-square test for categorical data; educational level: high = university or higher education, medium = vocational training,
low = primary or secondary education or less; Marital status: partner = married or cohabiting, no partner = divorced, widowed, or never married/
cohabited; A: Low level defined as GI symptom scale score < 30, high level defined as GI symptom scale score ≥ 30
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fatigue, nausea, pain, dyspnea, insomnia, appetite loss, consti-
pation or diarrhea, hormonal symptoms, neuropathy, and other
chemotherapy side effects compared to those without GI com-
plaints. One other study showed that GI symptoms appeared to
be moderately correlated with HRQoL including social func-
tioning, pain, and the nausea/vomiting [27]. It is unclear wheth-
er these issues are fully due to OC or due to treatment (surgery
or chemotherapy) or other physiologic causes.
Our study showed that prevalence of GI symptoms in pa-
tients with recurrent disease is higher in those of survivors
without recurrent disease. OC survivors with recurrent disease
had lower scored on HRQoL scales for global QoL and higher
scores on symptom scales. This could be interpreted as side
effects of further treatment that patients have to undergo be-
cause of recurrent disease. Initial treatment as well as treatment
for recurrent OC includes chemotherapy that causes consider-
able toxicity, such as nausea, vomiting, lack of appetite, alope-
cia, weakness, and fatigue [35]. Symptoms such as peripheral
neuropathy are to a large extent irreversible, while others such
as GI symptoms, pain, and fatigue or psychological problems
can potentially be treated if identified early [36]. These symp-
toms usually disappear over time after treatment completion.
GI symptoms were associated with HRQoL, regardless of the
presence of recurrent disease. GI complaints might probably be
related to the sequelae of the initial treatment consisting of sur-
gery followed by systemic treatment with chemotherapy or re-
current disease. Unfortunately, we did not record specific data on
chemotherapeutic regimen, surgical outcome, pre-existent per-
formance status, or complications during treatment as possible
explanations for persisting GI symptoms during survivorship.
Clinical implications
Care provided to OC patients should not be stopped when the
treatment ends because many women continue to experience
complaints after their cancer treatment [36]. During transition
from patient to survivor, patients lose contact with their cancer
caregiver and they are challenged to resume former roles in
life, even while they experience problems [37]. Therefore,
symptom management is important to maintain HRQoL of
OC survivors. A recently published review [38] showed ben-
efits of interventions such as cognitive behavioral therapy and
motivational interviewing as effective interventions to help
patients to cope with physical and psychological problems,
especially for women in whom the presence of GI symptoms
acts as a reminder of the disease. As of yet, no instrument for
symptom monitoring or interventions for persistent GI symp-
toms exist, except interventions that reduce burden of sequel-
ae. Therefore, further research after causes of GI symptoms is
warranted to uncover possibilities for symptom management
and patient consultation.
Strengths and limitations
The strengths of the current study are that it is a population-
based multicenter study design and it uses standardized and
validated questionnaires. However, our study also has several
limitations. The findings are based on cross-sectional data;
this means that causal relationships could not be determined.
In a study performed with a longitudinal design, analyses
stratified by surgical outcomes would be possible. In addition,
the results could have been affected by survivorship bias due
to aggressiveness of the disease and low survival rates [39]. Of
all selected patients, only 40% was still alive at time of inclu-
sion. Detailed information about the health status of non-
respondents is lacking (our response rate was 55% of whom
we had to exclude 31% due to lacking data on recurrent dis-
ease). Furthermore, analyses on recurrent disease could not be
performed due to small numbers of participants. Still, our
sample may be considered representative for the OC popula-
tion: from literature 5-year survival rate is at around 40%, but
90% for early stage disease [6, 13]. Prior research revealed
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that 10 to 50% of the OC survivors reported GI symptoms [19,
36, 40].We interpret these differences due to different survival
time from previous studies, and we included a heterogeneous
population including patients with and without recurrent dis-
ease and we excluded those with missing data.
In conclusion, a substantial proportion (20%) of OC survi-
vors experience GI symptoms that are similar to first presen-
tation, despite the fact that a large proportion does not have
recurrent disease. Health care professionals should be aware
of the persistence of presenting symptoms during survivor-
ship, affecting domains of functioning in daily life.
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